Bio + Health

Investing in Alchemy

Julie Yoo and Jay Rughani Posted October 15, 2024

Your access to life-saving medications shouldn’t depend on your zip code. Yet, for millions of Americans, especially in rural areas or lower-income communities, that is the reality.

Despite pharmaceutical spending in the US reaching over $700 billion each year, wide disparities in access to medications persist. The resulting inequities are particularly acute for rural communities and lower-income families, as well as for certain stigmatized populations such as those living with HIV or Hepatitis C (HCV).

Further, the clinics intended to serve these very groups, such as Federally Qualified Health Centers (FQHCs), Ryan White Clinics, and Sexually Transmitted Disease Clinics, often struggle to stay afloat financially. In particular, they lack the capabilities and capital needed to build and manage their own in-house pharmacies, leaving patients who use these clinics disadvantaged relative to those receiving care at larger medical groups and hospitals. Nine out of ten large hospitals now offer their patients access to an on-site specialty pharmacy. Yet, less than 20% of these safety net clinics have one. This is an unacceptable status quo.

Today, we are thrilled to announce our investment in Alchemy as they work to better connect our life sciences and healthcare delivery systems and solve these supply-demand mismatches in the pharmaceutical value chain.

Alchemy has emerged to empower the long tail of independent providers with the physical, clinical, and digital infrastructure they need to fully serve their patient communities effectively and profitably. With Alchemy’s pharmacy operating system and managed services platform, clinics are able to incorporate medication fulfillment into their core service model, which allows them to capture more of the economics, which further allows them to reinvest into their core clinical operations. Ultimately, Alchemy enables the most economically challenged healthcare providers to provide better care to the most marginalized patient groups, with medications access as the keystone.

In other industries, we have seen technology companies that empower the long tail of small and medium-sized businesses (SMBs) unlock massive market opportunities. Toast revolutionized the restaurant industry by giving independent businesses the digital tools they need to compete with large chains. Shopify did the same for e-commerce, turning millions of small merchants into global brands. Square transformed how small businesses handle payments, empowering them to operate as efficiently as larger enterprises. Alchemy is applying the same principles to the healthcare sector—by giving underserved clinics the infrastructure to run their own pharmacies, they are unlocking a multi-billion-dollar opportunity while simultaneously solving a critical societal challenge.

There are few stronger examples of founder-market fit than Alchemy’s founding team: Sid Viswanathan, serial entrepreneur, was cofounder, president, and eventual CEO at Truepill. He’s been through the highs and lows of startup building at scale and knows “the hard thing about hard things,” quite literally. Peter Park, who previously worked closely with Sid on a variety of pharmacy innovations, founded businesses focused on people living with HIV in Africa. He and Susie Crowe, Alchemy’s Chief Pharmacist, spent years providing quality HIV care for patients across Kenya, and facilitating the dispensing of essential medicines to patients who otherwise would not have had access to them. Collectively, they have spent 18 years in Africa building the largest HIV access program in the world, and have set up, operated, and scaled pharmacies that have dispensed over 25 million prescriptions to patients across all 50 states in the US. It’s not an exaggeration to say that bringing medications to those in need is a life calling for all three of them.

We could not be more excited to partner with this incredible team to take on the challenge of making key medications more accessible to those who need them. By giving clinics the tools to not just survive but thrive, Alchemy is laying the foundation for a more equitable healthcare system.

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Fintech

new Investing in Glimpse

Joe Schmidt and David Haber
Infra

new Investing in Deeptune

Marco Mascorro and Martin Casado
Growth

Investing in Mind Robotics

Sarah Wang
Growth

Investing in Nexthop AI

Raghu Raghuram, Shangda Xu, and Guido Appenzeller
Fintech

Investing in Lio

Seema Amble, James da Costa, Eric Zhou, and Brian Roberts

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.